drugset
drugset / Trial / NCT04576390

Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP

NCT04576390 ↗

Phase 4 Unknown 90 enrolled Theodor Bilharz Research Institute Cairo University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to compare the effects of a single dose Ondansetron 4mg versus Palonosetron 75mcg in the prophylaxis against early \& delayed postoperative nausea and vomiting in the first 48 hours post-operatively in patients undergoing Endoscopic Retrograde Cholangio-Pancreatography (ERCP) to determine the complete response, complete control and failure rates.

Timeline

Start
2020-10-24
Primary completion
2021-04-30
Completion
2021-05-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 4 mg —
Comparator Palonosetron Other / unclassified 75 ug —

Indications

No indication recorded.